ArticleMaterials (Basel, Switzerland)2026
Investigation on the Fatigue and Rutting Behavior of Asphalt Binder Containing Compound Warm Mixing Agent.
Article in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A composite warm-mix additive (PNSK) was developed to improve asphalt workability by reducing viscosity while maintaining rheological performance at both high and low temperatures. The warm-mix asphalt binders (PWMA) were analyzed using an integrated approach combining conventional property tests with rheological analysis. Results showed that penetration, softening point, and ductility improved. The viscosity-reduction effect was enhanced with increasing PNSK dosage, yet the benefit plateaued beyond 11% content. Additionally, the adhesion strength between asphalt and aggregate began to decrease after 11% dosage, with 12% serving as the critical threshold for adhesion deterioration. Consequently, the optimal dosage was determined to be 11% based on comprehensive consideration of all factors. LAS results demonstrated that 11%PWMA exhibited lower strain sensitivity and superior fatigue resistance at low-to-intermediate temperatures, with fatigue life increasing by nearly an order of magnitude under low strain at 20 °C. MSCR results revealed that under low stress, 11%PWMA exhibited significantly lower non-recoverable creep compliance (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.